Dividends & Buybacks ·
United Therapeutics Corporation entered into an accelerated share repurchase agreement with Citibank to repurchase…
UTHRUNITED THERAPEUTICS Corp
United Therapeutics Corporation entered into an accelerated share repurchase agreement with Citibank to repurchase approximately $477.6 million of its common stock, utilizing the remainder of its previously announced $2 billion authorization. The company will make an upfront payment on or around September 10, 2026, and receive an initial delivery of approximately 719,376 shares, representing roughly 75% of the anticipated total repurchase based on the closing price on September 8, 2026. Final settlement is expected in the fourth quarter of 2026, with the exact share count determined by the average daily volume-weighted average price during the agreement term. This transaction brings total shareholder returns to approximately $4 billion over the past 2.5 years. United Therapeutics operates in the biotechnology industry, focusing on discovering cures and treatments for rare diseases such as pulmonary arterial hypertension.